{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T04:07:11Z","timestamp":1752984431463,"version":"3.32.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,3,22]],"date-time":"2006-03-22T00:00:00Z","timestamp":1142985600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2006,9,25]]},"DOI":"10.1007\/s10067-006-00243-0","type":"journal-article","created":{"date-parts":[[2006,3,21]],"date-time":"2006-03-21T08:50:27Z","timestamp":1142931027000},"page":"882-884","source":"Crossref","is-referenced-by-count":19,"title":["Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study"],"prefix":"10.1007","volume":"25","author":[{"given":"Liisa","family":"Konttinen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eeva","family":"Kankaanp\u00e4\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riitta","family":"Luosuj\u00e4rvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harri","family":"Bl\u00e5field","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaisa","family":"Vuori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markku","family":"Hakala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vappu","family":"Rantalaiho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elina","family":"Savolainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toini","family":"Uutela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"ROB-FIN Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,3,22]]},"reference":[{"key":"243_CR1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/art.20115","volume":"50","author":"MH Buch","year":"2004","unstructured":"Buch MH, Bingham SJ, Seto Y, McGonagle D, Bejarno V, White J et al (2004) Lack of response to anakinra in rheumatoid arthritis following of tumor necrosis factor alpha blockade. Arthritis Rheum 50:725\u2013728","journal-title":"Arthritis Rheum"},{"key":"243_CR2","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/art.20640","volume":"50","author":"T Saxne","year":"2004","unstructured":"Saxne T, Larsson L, Geborek P (2004) Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis alpha blockade: comment on the article by Buch et al. Arthritis Rheum 50:3049\u20133050","journal-title":"Arthritis Rheum"},{"key":"243_CR3","unstructured":"Schiff MH, Keystone EC, Gibofsky A, Markenson JA, Weaver A, Xia HA et al (2004) Efficacy of Anakinra in patients with rheumatoid arthritis previously refractory to TNF antagonists. ACR 2004, abstract 920"},{"key":"243_CR4","first-page":"119","volume":"4","author":"HE Langer","year":"2003","unstructured":"Langer HE, Missler-Karger B (2003) Kineret: efficacy and safety in daily clinical practice: an interim analysis of the Kineret response assessment initiative (Kreative) protocol. Int J Clin Pharm Res 4:119\u2013128","journal-title":"Int J Clin Pharm Res"},{"key":"243_CR5","doi-asserted-by":"crossref","unstructured":"Den Broeder AA, de Jong E, Franssen MJ, Jeurissen ME, Flendrie M, van den Hoogen FH (2005) Observational study on efficacy, safety and drug-survival of anakinra in RA patients in clinical practice. Ann Rheum Dis [Epubl ahead of print]","DOI":"10.1136\/ard.2004.033662"},{"key":"243_CR6","doi-asserted-by":"crossref","unstructured":"Nordstr\u00f6m D, Konttinen L, Korpela M, Tiipana-Kinnunen T, Eklund K, Forsberg S et al (2005) Performance study of patients using traditional anti-rheumatic drugs in combination with infliximab: The Finnish perspective. Rheumatol Int [Epubl ahead of print]","DOI":"10.1007\/s00296-005-0054-7"},{"key":"243_CR7","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","volume":"41","author":"B Breshnihan","year":"1998","unstructured":"Breshnihan B, Alvaro-Gracia J, Cobby M, Doherty M, Domljan Z, Emery P et al (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41:2196\u20132204","journal-title":"Arthritis Rheum"},{"key":"243_CR8","first-page":"225","volume":"30","author":"SB Cohen","year":"2003","unstructured":"Cohen SB, Wooley JM, Chan W (2003) Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J Rheumatol 30:225\u2013231","journal-title":"J Rheumatol"},{"key":"243_CR9","first-page":"649","volume":"31","author":"J Tessler","year":"2004","unstructured":"Tessler J, Fleischman R, Dore R, Bennett R, Solinger A, Joh T et al (2004) Concomitant medication use in a large, international, multicenter, placebo controlled trial on anakinra, a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis. J Rheumatol 31:649\u2013654","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-006-00243-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-006-00243-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-006-00243-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T02:28:46Z","timestamp":1736303326000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-006-00243-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,22]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,9,25]]}},"alternative-id":["243"],"URL":"https:\/\/doi.org\/10.1007\/s10067-006-00243-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2006,3,22]]}}}